Press Release: Locus Cell

Locus Cell Named "Emerging CDMO of the Year" at the Asia-Pacific Biopharma Excellence Awards 2025

12 March 2025 | Singapore – Locus Cell has been recognized as the "Emerging CDMO of the Year" at the prestigious Asia-Pacific Biopharma Excellence Awards 2025, a testament to its outstanding contributions to bioprocessing and contract development and manufacturing in the region.

The Asia-Pacific Biopharma Excellence Awards celebrate exceptional achievements across the biopharmaceutical industry, recognizing leaders in bioprocessing, logistics, supply chain management, and clinical trials. This accolade underscores Locus Cell’s rapid growth, commitment to innovation, and excellence in supporting biologics and advanced therapies.

As a rising Contract Development and Manufacturing Organization (CDMO), Locus Cell has distinguished itself through cutting-edge bioprocessing technologies, strategic partnerships, and a commitment to regulatory excellence. With a focus on delivering tailored solutions for biologics and cell therapies, the company is set to redefine industry standards and accelerate breakthroughs in regenerative medicine.
‍
“We are deeply honored to receive this recognition from ABEA. It is not only an encouragement to the Locus Cell team but also a meaningful acknowledgment of the immense potential within Taiwan’s cell therapy sector. This award fuels our commitment to advancing innovation and excellence in regenerative medicine,” said Dr. Yu Hsiang Chang, Locus Cell. ‍

The Asia-Pacific Biopharma Excellence Awards 2025 brought together key industry players to celebrate innovation and leadership, reinforcing Singapore’s role as a hub for biopharmaceutical advancements.

‍About Locus Cell‍
Locus Cell is a leading CDMO specializing in biopharmaceutical development and manufacturing, with expertise in advanced therapy medicinal products (ATMPs). The company provides end-to-end solutions to accelerate the journey from discovery to commercialization.

‍